Insider · CIK 0002085122
Guy Warren Primus
Files at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). First filing -, latest -.
In brief
Guy Warren Primus files SEC Form 4 as director at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Guy Warren Primus has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 40,000 | Jul 2, 2026 |
| Apr 15, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Common Stock | +25,000 | - | - | 25,000 | Apr 17, 2026 |
| Apr 15, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 17, 2026 |
| Dec 24, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 29, 2025 |
Questions about Guy Warren Primus
Answered from the filings on this page, as of the latest one.
Is Guy Warren Primus buying or selling?
Guy Warren Primus has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Guy Warren Primus's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Guy Warren Primus has 0.
Where does Guy Warren Primus file Form 4?
Guy Warren Primus has filed Form 4 at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.